| 2026-03-31 |
复牌提示：
2026-03-30 19:50:00 停牌，复牌日期 2026-03-31 09:00:00
|
| 2026-03-30 |
详情>>
业绩披露：
2025年年报每股收益0.00美元,归母净利润-1729.8万美元,同比去年增长12.60%
|
| 2026-03-17 |
详情>>
股本变动：
变动后总股本114.46万股
|
| 2026-03-17 |
详情>>
拆分方案：
每40.0000合并分成1.0000股
|
| 2026-02-02 |
股东大会：
将于2026-03-02召开股东大会
会议内容 ▼▲
- 1.To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the exercisability of Series G Warrants to purchase up to an aggregate of 10,043,774 American Depositary Shares (“ADSs”) and Placement Agent Warrants to purchase up to an aggregate of 504,300 ADSs, and the issuance of the ADSs and ordinary shares underlying such warrants, which were issued in connection with a registered direct offering and a concurrent private placement that closed on December 17, 2025 and January 20, 2026.
2.To approve, for purposes of complying with Nasdaq Listing Rule 5635(c), the exercisability of Pre-Funded Warrants to purchase up to an aggregate of 2,563,713 ADSs and Series G Warrants to purchase up to an aggregate of 2,563,713 ADSs and the issuance of the ADSs and ordinary shares underlying such warrants, which were issued in connection with a private placement offering of securities of the Company that closed on December 23, 2025.
3.To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the exercisability of Pre-Funded Warrants to purchase up to an aggregate of 2,563,713 ADSs and Series G Warrants to purchase up to an aggregate of 2,563,713 ADSs and the issuance of the ADSs and ordinary shares underlying such warrants, which were issued in connection with a private placement offering of securities of the Company that closed on December 23, 2025.
4.To approve, for purposes of complying with Nasdaq Listing Rule 5635(c), the exercisability of Pre-Funded Warrants to purchase up to an aggregate of 4,673,963 ADSs and Note Exchange Warrants to purchase up to an aggregate of 4,673,963 ADSs and the issuance of the ADSs and ordinary shares underlying such warrants, which were issued in connection with an exchange of notes that closed on December 17, 2025.
5.To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the exercisability of Pre-Funded Warrants to purchase up to an aggregate of 9,502,703 ADSs and Note Exchange Warrants to purchase up to an aggregate of 9,502,703 ADSs and the issuance of the ADSs and ordinary shares underlying such warrants, which were issued in connection with an exchange of notes that closed on December 17, 2025.
|
| 2025-11-17 |
股东大会：
将于2025-12-15召开股东大会
会议内容 ▼▲
- 1.To approve, in accordance with Nasdaq Listing Rule 5635(d), the exercisability of certain warrants and the issuance of the ordinary shares underlying such warrants, which warrants were issued in connection with an offering of securities of the Company that closed on October 16, 2025 (the “Warrant Exercise Proposal”).
2.In accordance with section 618 of the U.K. Companies Act 2006 (the “Companies Act”), and subject to and conditional upon the passing of Resolutions 3, 4, 5 and 6, each of the ordinary shares of USD 0.0001 in the capital of the Company be sub-divided and, as applicable, re-designated into one Ordinary Share of USD 0.000000005 each and 19,999 deferred shares of USD 0.000000005 each (the “Deferred Shares”), such shares having the rights and being subject to the restrictions as set out in the New Articles (as defined below) (the “Reduction in Nominal Value Proposal”).
3.That subject to and conditional upon the passing of Resolutions 2, 4, 5 and 6, and in accordance with section 551 of the Companies Act, the Company’s directors or any duly authorised committee of the directors be generally and unconditionally authorised to allot shares in the Company and to grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of USD 3,000 for a period expiring on June 30, 2030 (unless otherwise renewed, varied or revoked by the Company at a general meeting), save that the Company may, before such expiry, make offers or agreements which would or might require such shares to be allotted or such rights to be granted after such expiry and the directors may allot such shares or grant such rights in pursuance of such offers or agreements notwithstanding that the authority conferred by this resolution has expired; this resolution revokes and replaces all unexercised authorities previously granted to the directors to allot shares or grant rights to subscribe for or convert any security into shares, but without prejudice to any allotment of shares or grant of rights already made, offered or agreed to be made pursuant to such authorities (the “General Allotment Proposal”).
4.That subject to and conditional upon the passing of Resolutions 2, 3, 5 and 6, the share buyback contract in the form produced to the Meeting, to be entered into between the Company and each of the shareholders (in their capacity as holders of Deferred Shares) for the purchase by the Company of all the Deferred Shares, be approved and its terms authorized for the purposes of section 694 of the Companies Act, but so that the approval and authority expire on December 15, 2026 (the “Buyback Proposal”);
5.That subject to and conditional upon the passing of Resolutions 2, 3, 4, and 6, in accordance with section 570 of the Companies Act, the directors of the Company (or any duly authorised committee of the directors of the Company) be generally and unconditionally empowered to allot equity securities (as defined in section 560 of the Companies Act) for cash pursuant to the authorisation conferred on them as if section 561 of the Companies Act and any pre-emption provisions in the Articles (or howsoever otherwise arising) did not apply to the allotment for a period expiring (unless previously renewed, varied or revoked by the Company prior to or on that date) five years after the date on which this resolution is passed save that the Company may, before such expiry, make an offer or agreement which would or might require shares to be allotted after such expiry and the directors may allot shares in pursuance of any such offer or agreement notwithstanding that the power conferred by this resolution has expired (the “Pre-emption Rights Proposal”).
6.That subject to and conditional upon the passing of Resolutions 2, 3, 4, and 5, the draft Articles of Association produced to the Meeting (the “New Articles”) be adopted as the articles of association in substitution for, and to the exclusion of the Company’s existing articles of association (the “New Articles Proposal”).
|
| 2025-11-13 |
详情>>
业绩披露：
2025年三季报(累计)每股收益0.00美元,归母净利润-1200万美元,同比去年增长25.09%
|
| 2025-11-01 |
详情>>
内部人交易：
Farag Kameel D.共交易2笔
|
| 2025-08-13 |
详情>>
业绩披露：
2025年中报每股收益0.00美元,归母净利润-560万美元,同比去年增长57.33%
|
| 2025-06-06 |
股东大会：
将于2025-06-30召开股东大会
会议内容 ▼▲
- 1.To receive the report of the Board of Directors and the accounts for the year ended December 31, 2024, together with the report of the statutory auditor and the strategic report.
2.To approve, on an advisory basis, the Board of Directors’ Remuneration Report (excluding the Board of Directors’ Remuneration Policy), as set out in the Company’s annual report and accounts for the financial year ended December 31, 2024.
3.To re-elect Hoyoung Huh as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Company’s articles of association (the “Articles”).
4.To re-elect Robert Bazemore as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
5.To re-elect James Neal as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
6.To re-elect Sandip I. Patel as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
7.To re-elect Samir R. Patel as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
8.To re-elect Abizer Gaslightwala as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
9.To ratify the appointment of BDO USA, P.C. as independent registered public accounting firm of Akari for the year ending December 31, 2025.
10.To re-appoint HaysMac LLP as statutory auditors of Akari to hold office until the conclusion of the next annual general meeting at which accounts are laid before Akari shareholders.
11.To authorize the audit committee of the Board of Directors of Akari to fix the statutory auditors’ remuneration.
12.To generally and unconditionally authorize an increase in the number of shares available for the grant of awards under the Company’s 2023 Equity Incentive Plan (the “2023 Plan”) by 11,026,000,000 ordinary shares (the equivalent of 5,513,000 American Depositary Shares (“ADSs”)) to 19,806,000,000 ordinary shares (the equivalent of 9,903,000 ADSs) plus such additional number of ordinary shares (up to 855,637,300 ordinary shares) subject to awards granted under the Celsus Therapeutics PLC 2014 Equity Incentive Plan (the “2014 Plan”), to the extent such awards are forfeited or cancelled, or expire unexercised.
13.To approve, on a non-binding, advisory basis, the compensation of our named executive officers (“NEOs”) as disclosed in the Proxy Statement.
14.To approve the time-vested one time grant stock option awards over 225,000 ADSs (representing 450,000,000 ordinary shares) granted, conditional on shareholder approval, to each of certain of the Company’s directors (being Hoyoung Huh, Raymond Prudo-Chlebosz, Robert Bazemore, James Neal, Sandip I. Patel and Samir R. Patel) on March 20, 2025 (the “Stock Option Awards”), which would represent, in aggregate, time-vested one time grant options over 1,350,000 ADSs (representing 2,700,000,000 ordinary shares) (4.2% of the Company’s current issued share capital) with each of the Stock Option Awards vesting 25% on March 20, 2025, 25% at December 31, 2025 and the remaining 50% vesting monthly over the next 24 months thereafter.
15.That, in accordance with section 551 of the U.K. Companies Act 2006, our directors or any duly authorized committee of the directors be generally and unconditionally authorized to allot shares in Akari and to grant rights to subscribe for or to convert any security into shares in Akari up to an aggregate nominal amount of $20,000,000 for a period expiring (unless otherwise renewed, varied or revoked by Akari at a general meeting) on June 30, 2030, save that Akari may, before such expiry, make offers or agreements which would or might require such shares to be allotted or such rights to be granted after such expiry and the directors may allot such shares or grant such rights in pursuance of such offers or agreements notwithstanding that the authority conferred by this resolution has expired; this resolution revokes and replaces all unexercised authorities previously granted to the directors to allot shares or grant rights to subscribe for or convert any security into shares, but without prejudice to any allotment of shares or grant of rights already made, offered or agreed to be made pursuant to such authorities.
16.That, conditional on resolution 15 above (the “General Allotment Proposal”) being duly passed, in accordance with section 570 of the U.K. Companies Act 2006, the directors of Akari (or any duly authorized committee of the directors of Akari) be generally empowered to allot equity securities (as defined in section 560 of the U.K. Companies Act 2006) for cash pursuant to the authorization conferred on them by the General Allotment Proposal as if section 561 of the U.K. Companies Act 2006 and any pre-emption provisions in the Articles (or howsoever otherwise arising) did not apply to the allotment for a period expiring (unless previously renewed, varied or revoked by Akari prior to or on that date) five years after the date on which this resolution is passed save that Akari may, before such expiry, make an offer or agreement which would or might require shares to be allotted after such expiry and the directors may allot shares in pursuance of any such offer or agreement notwithstanding that the power conferred by this resolution has expired (the “Pre-emption Rights Proposal”).
|
| 2025-04-15 |
详情>>
业绩披露：
2024年年报每股收益0.00美元,归母净利润-1979.1万美元,同比去年增长-97.75%
|
| 2024-11-19 |
详情>>
业绩披露：
2024年三季报(累计)每股收益0.00美元,归母净利润-1601.9万美元,同比去年增长-172.9%
|
| 2024-08-19 |
详情>>
业绩披露：
2024年中报每股收益0.00美元,归母净利润-1312.4万美元,同比去年增长-337.67%
|
| 2024-06-03 |
股东大会：
将于2024-06-27召开股东大会
会议内容 ▼▲
- 1.To receive the report of the Board of Directors and the accounts for the year ended December 31, 2023, together with the report of the statutory auditor and the strategic report.
2.To approve the Board of Directors’ Remuneration Report (excluding the Board of Directors’ Remuneration Policy), as set out in the Company’s annual report and accounts for the financial year ended December 31, 2023.
3.To re-elect Donald Williams as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Company’s articles of association (the “Articles”).
4.To re-elect Michael Grissinger as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
5.To re-elect Mohamed Wa’El Ahmed Hashad as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
6.To re-elect Samir Patel as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
7.To re-elect Raymond Prudo-Chlebosz, M.D. as a director of Akari, as a Class C Director as stated in Article 18.2.3 of the Articles.
8.To ratify the appointment of BDO USA, P.C. as independent registered public accounting firm of Akari for the year ending December 31, 2024.
9.To ratify the appointment of Haysmacintyre LLP as statutory auditors of Akari to hold office until the conclusion of the next annual general meeting at which accounts are laid before Akari shareholders.
10.To authorize the audit committee of the Board of Directors of Akari to fix the statutory auditors’ remuneration.
11.To approve, on a non-binding, advisory basis, the compensation of our named executive officers (“NEOs”) as disclosed in this Proxy Statement.
12.To indicate, on a non-binding, advisory basis, the preferred frequency of future shareholder advisory votes on the compensation of Akari’s NEOs.
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益0.00美元,归母净利润-556.6万美元,同比去年增长-656.04%
|
| 2024-03-29 |
详情>>
业绩披露：
2023年年报每股收益0.00美元,归母净利润-1000.8万美元,同比去年增长43.61%
|
| 2023-09-29 |
详情>>
业绩披露：
2023年中报每股收益0.00美元,归母净利润-299.86万美元,同比去年增长72.38%
|
| 2023-08-17 |
详情>>
拆分方案：
每20.0000合并分成1.0000股
|
| 2023-06-06 |
股东大会：
将于2023-06-30召开股东大会
会议内容 ▼▲
- 1.To receive the report of the Directors and the accounts for the year ended December 31, 2022, together with the report of the statutory auditor and the strategic report.
2.To approve the Directors’ Remuneration Report (excluding the Directors’ Remuneration Policy, as set out on pages 23 to 29 of the Directors’ Remuneration Report), as set out in the Company’s annual report and accounts for the financial year ended 31 December 2022.
3.To approve the Directors’ Remuneration Policy, as set out on pages 23 to 29 of the Directors’ Remuneration Report.
4.To re-elect James Hill, M.D. as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Company’s Articles of Association (the “Articles”).
5.To re-elect Stuart Ungar, M.D. as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
6.To re-elect David Byrne as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
7.To re-elect Donald Williams as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
8.To re-elect Michael Grissinger as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
9.To ratify the appointment of BDO USA, LLP as independent registered public accounting firm of Akari for the year ending December 31, 2023.
10.To re-appoint Haysmacintyre LLP as statutory auditors of Akari to hold office until the conclusion of the next annual general meeting at which accounts are laid before Akari shareholders.
11.To authorize the audit committee of the Board of Directors of Akari to fix the statutory auditors’ remuneration.
12.To authorize the adoption of a new equity plan (the “2023 Plan”), with 980,000,000 ordinary shares in the capital of the Company available for the grant of awards under the 2023 Plan, the principal terms of which are summarized in the Appendix to the Proxy Statement (including that the directors of Akari are authorized to do all acts and things which they may consider necessary or expedient to implement and operate the 2023 Plan).
13.That, in accordance with section 551 of the Companies Act 2006, the directors be generally and unconditionally authorized to allot shares in the Company and to grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of USD3,500,000, provided that this authority shall, unless renewed, varied or revoked by the Company, expire on June 30, 2028, save that the Company may, before such expiry, make offers or agreements which would or might require such shares to be allotted or such rights granted after such expiry and the directors may allot such shares or grant such rights in pursuance of such offers and agreements notwithstanding that the authority conferred by this resolution has expired; and this resolution revokes and replaces all unexercised authorities previously granted to the directors to allot shares or grant rights to subscribe for or convert any security into shares, but without prejudice to any allotment of shares or grant of rights already made, offered or agreed to be made pursuant to such authorities.
14.That with effect from the conclusion of the Meeting, the Articles be amended by deleting article 15.2 of the Articles and replacing it with the following new article 15.2.
15.That, in accordance with section 570 of the Companies Act 2006, the directors be authorized to allot equity securities (as defined in section 560 of the Companies Act 2006) for cash pursuant to the authorization granted by resolution 13 above and/or to sell ordinary shares held by the Company as treasury shares as if section 561 of the Companies Act 2006 did not apply to any such allotment or sale, provided that this authority shall, unless renewed, varied or revoked by the Company, expire on June 30, 2028, save that the Company may, before such expiry, make offers or agreements which would or might require such equity securities to be allotted or treasury shares to be sold after such expiry and the directors may allot such equity securities or sell treasury shares in pursuance of such offers and agreements notwithstanding that the authority conferred by this resolution has expired.
|
| 2022-06-07 |
股东大会：
将于2022-06-30召开股东大会
会议内容 ▼▲
- 1.To receive the report of the Directors and the accounts for the year ended December 31, 2021, together with the report of the statutory auditor, the Directors’ Remuneration Report and the strategic report.
2.To approve the Directors’ Remuneration Report (other than the part containing the directors' remuneration policy).
3.To re-elect James Hill, M.D. as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles of Association of Akari (the “Articles”).
4.To re-elect Stuart Ungar, M.D. as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
5.To re-elect David Byrne as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
6.To re-elect Donald Williams as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
7.To re-elect Michael Grissinger as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
8.To re-elect Rachelle Jacques as a director of Akari, as a Class B Director as stated in Article 18.2.2 of the Articles.
9.To ratify the appointment of BDO USA, LLP as independent registered public accounting firm of Akari for the year ending December 31, 2022.
10.To re-appoint Haysmacintyre LLP as statutory auditors of Akari to hold office until the conclusion of the next annual general meeting at which accounts are laid before Akari shareholders.
11.To authorize the audit committee of the Board of Directors of Akari to fix the statutory auditors’ remuneration.
12.To generally and unconditionally authorize an increase in the number of shares available for the grant of awards under the Company’s 2014 Equity Incentive Plan (the “2014 Plan”) to 890,000,000 ordinary shares.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-06-07 |
股东大会：
将于2021-06-30召开股东大会
会议内容 ▼▲
- 1.To receive the reports of the Directors and the accounts for the year ended December 31, 2020, together with the report of the statutory auditor and the strategic report.
2.To approve the Directors’ Remuneration Report (other than the part containing the directors' remuneration policy).
3.To re-elect James Hill, M.D. as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles of Association of Akari (the “Articles”).
4.To re-elect Stuart Ungar, M.D. as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
5.To re-elect David Byrne as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
6.To re-elect Donald Williams as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
7.To re-elect Michael Grissinger as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
8.To re-elect Peter Feldschreiber as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
9.To re-elect Clive Richardson as a director of Akari, as a Class B Director as stated in Article 18.2.2 of the Articles.
10.To re-elect Raymond Prudo-Chlebosz, M.D. as a director of Akari, as a Class C Director as stated in Article 18.2.3 of the Articles.
11.To ratify the appointment of BDO USA, LLP as independent registered public accounting firm of Akari for the year ending December 31, 2021.
12.To re-appoint Haysmacintyre as statutory auditors of Akari to hold office until the conclusion of the next annual general meeting at which accounts are laid before Akari shareholders.
13.To authorize the audit committee of the Board of Directors of Akari to fix the statutory auditors’ remuneration.
14.That, in accordance with section 551 of the Companies Act 2006, the directors be generally and unconditionally authorized to allot shares in the Company and to grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of USD1,500,000, provided that this authority shall, unless renewed, varied or revoked by the Company, expire on June 30, 2026, save that the Company may, before such expiry, make offers or agreements which would or might require such shares to be allotted or such rights granted after such expiry and the directors may allot such shares or grant such rights in pursuance of such offers and agreements notwithstanding that the authority conferred by this resolution has expired; and this resolution revokes and replaces all unexercised authorities previously granted to the directors to allot shares or grant rights to subscribe for or convert any security into shares, but without prejudice to any allotment of shares or grant of rights already made, offered or agreed to be made pursuant to such authorities.
15.To generally and unconditionally authorize an increase in the number of shares available for the grant of awards under the Company’s 2014 Equity Incentive Plan (the “2014 Plan”) to 400,000,000 ordinary shares.
16.That, in accordance with section 570 of the Companies Act 2006, the Directors be authorized to allot equity securities (as defined in section 560 of the Companies Act 2006) for cash pursuant to the authorization granted by resolution 14 above and/or to sell ordinary shares held by the Company as treasury shares as if section 561 of the Companies Act 2006 did not apply to any such allotment or sale, provided that this authority shall, unless renewed, varied or revoked by the Company, expire on June 30, 2026, save that the Company may, before such expiry, make offers or agreements which would or might require such equity securities to be allotted or treasury shares to be sold after such expiry and the directors may allot such equity securities or sell treasury shares in pursuance of such offers and agreements notwithstanding that the authority conferred by this resolution has expired.
|
| 2020-11-16 |
股东大会：
将于2020-12-08召开股东大会
会议内容 ▼▲
- 1.To consider and, if thought fit, passing the resolution specified in the Notice of Meeting (the “Resolution”).
|
| 2020-06-01 |
股东大会：
将于2020-06-30召开股东大会
会议内容 ▼▲
- Ordinary Business
1.To receive the reports of the Directors and the accounts for the year ended December 31, 2019, together with the report of the statutory auditor and the strategic report.
2.To approve the Directors’ Remuneration Report (other than the part containing the directors' remuneration policy).
3.To re-elect Stuart Ungar, M.D. as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles of Association of Akari (the “Articles”).
4.To re-elect James Hill, M.D. as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
5.To re-elect David Byrne as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
6.To re-elect Donald Williams as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
7.To re-elect Peter Feldschreiber as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
8.To re-elect Michael Grissinger as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles.
9.To ratify the appointment of BDO USA, LLP as independent registered public accounting firm of Akari for the year ending December 31, 2020.
10.To re-appoint Haysmacintyre as statutory auditors of Akari to hold office until the conclusion of the next annual general meeting at which accounts are laid before Akari shareholders.
11.To authorize the audit committee of the Board of Directors of Akari to fix the statutory auditors’ remuneration.
12.To approve the directors' remuneration policy, as set out in the directors' remuneration report.
13.To generally and unconditionally authorize an increase in the number of shares available for the grant of awards to 344,747,462 ordinary shares under the Company’s 2014 Equity Incentive Plan (the “2014 Plan”).
Special Business
14.To adopt the draft articles of association produced to the meeting (the “New Articles”) as the articles of association of the Company in substitution for, and to the exclusion of, the Company's existing articles of association.
|
| 2019-05-29 |
股东大会：
将于2019-06-27召开股东大会
会议内容 ▼▲
- 1.To receive the reports of the Directors and the accounts for the year ended December 31, 2018, together with the report of the statutory auditor and the strategic report.
2.To receive and adopt the Directors’ Remuneration Report (other than the part containing the Directors’ Remuneration Policy).
3.To re-elect Stuart Ungar, M.D., as a Class A Director of Akari as stated in Article 18.2.1 of the Articles of Association of Akari.
4.To re-elect James Hill, M.D., as a Class A Director of Akari as stated in Article 18.2.1 of the Articles of Association of Akari.
5.To re-elect David Byrne, as a Class A Director of Akari as stated in Article 18.2.1 of the Articles of Association of Akari.
6.To re-elect Donald Williams, as a Class A Director of Akari as stated in Article 18.2.1 of the Articles of Association of Akari.
7.To re-elect Peter Feldschreiber, as a Class A Director of Akari as stated in Article 18.2.1 of the Articles of Association of Akari.
8.To re-elect Michael Grissinger, as a Class A Director of Akari as stated in Article 18.2.1 of the Articles of Association of Akari.
9.To re-elect Clive Richardson, as a Class B Director of Akari as stated in Article 18.2.2 of the Articles of Association of Akari.
10.To ratify the appointment of BDO USA, LLP, as independent registered public accounting firm of Akari for the year ending December 31, 2019.
11.To re-appoint Haysmacintyre, as statutory auditors of Akari to hold office until the conclusion of the next annual general meeting at which accounts are laid before Akari shareholders.
12.To authorize the audit committee of the Board of Directors of Akari to fix the statutory auditors’ remuneration.
|
| 2018-08-17 |
股东大会：
将于2018-09-19召开股东大会
会议内容 ▼▲
- 1.To receive the reports of the Directors and the accounts for the year ended December 31, 2017, together with the report of the statutory auditor and the strategic report.
2.To receive and adopt the Directors’ Remuneration Report (other than the part containing the Directors’ Remuneration Policy).
3.To re-elect Stuart Ungar, M.D. as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles of Association of Akari.
4.To re-elect James Hill, M.D. as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles of Association of Akari.
5.To re-elect David Byrne as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles of Association of Akari.
6.To re-elect Donald Williams as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles of Association of Akari.
7.To re-elect Peter Feldschreiber as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles of Association of Akari.
8.To re-elect Michael Grissinger as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Articles of Association of Akari.
9.To re-elect Ray Prudo as a director of Akari, as a Class C Director as stated in Article 18.2.3 of the Articles of Association of Akari.
10.To ratify the appointment of BDO USA, LLP, as independent registered public accounting firm of Akari for the year ending December 31, 2018.
11.To re-appoint Haysmacintyre, as statutory auditors of Akari to hold office until the conclusion of the next annual general meeting at which accounts are laid before Akari shareholders.
12.To authorize the audit committee of the Board of Directors of Akari to fix the statutory auditors’ remuneration.
13.To generally and unconditionally authorize an increase in the number of shares available for the grant of awards to 183,083,207 ordinary shares under the Company’s 2014 Equity Incentive Plan (the “2014 Plan”).
|
| 2018-03-21 |
财报披露：
美东时间 2018-03-21 盘前发布财报
|
| 2017-06-29 |
股东大会：
将于2017-06-28召开股东大会
|
| 2016-04-28 |
股东大会：
将于2016-06-29召开股东大会
会议内容 ▼▲
- 1.To receive the accounts of the Company for the year ended December 31, 2015 together with the report of the auditors of the Company. The financial statements are presented and prepared in accordance with U.S. generally accepted accounting principles, and the financial statements are presented and prepared in accordance with International Financial Regulatory Standards (IFRS) for UK filing.
2.To re-elect Stuart Ungar, M.D. as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles of Association of Akari.
3.To re-elect James Hill, M.D. as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles of Association of Akari.
4.To elect David Byrne as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles of Association of Akari.
5.To elect Donald Williams as a director of Akari, as a Class A Director as stated in Article 19.2.1 of the Articles of Association of Akari.
6.To appoint BDO USA, LLP, as auditors of Akari to hold office until the conclusion of the next general meeting at which accounts are laid before Akari and to authorize the audit committee of the board of directors of Akari to fix the auditors’ remuneration.
|